IDH2 and glioblastoma: When we evaluated the prognostic value of TERTp mutations in each of the five groups by Cox regression analysis, we found no evidence of association, with the exception of Group 5 (IDH-WT GBM), in which we found by multivariate analysis that patients with TERTp mutation had statistically worse prognosis than patients with TERTp-WT (P = 0.045) [median survival with 95% CI: 16.4 months (13.012–19.516) vs. 13.0 months (1.021–25.039), respectively] (Table 5).